Kalshi and Polymarket open FDA decision markets
Kalshi and Polymarket this year began offering U.S. Food and Drug Administration decision contracts, letting users trade on pharmaceutical regulatory outcomes. The new category extends both platforms beyond their established political and economic markets. An academic paper published on SSRN examines oracle adjudication mechanisms on the two CFTC-regulated platforms, analyzing functional alignment and contestability between them.
FDA contracts give Kalshi and Polymarket a regulatory-grade use case that draws institutional capital from biotech funds and pharma analysts with real hedging needs. These traders bring larger positions and longer holding periods than election bettors, which deepens book depth and reduces the whipsaw price moves that plagued both platforms' thin macro markets.
The downside is tighter scrutiny: a single high-profile drug approval where insider trading or leaked data moves prices ahead of announcement would draw SEC and congressional attention to prediction markets as information-security risks. Both platforms must now build surveillance infrastructure they never needed for politics. The race is between Kalshi's first-mover liquidity advantage and Polymarket's sharper pricing on binary outcomes, with the winner capturing a recurring vertical that trades year-round instead of cycling with election calendars.
Kalshi and Polymarket's FDA expansion joins their recent college football and Fed-veterans markets as the platforms race beyond politics into regulated verticals that attract institutional flow.